Editor’s Note: At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.01 Clinical Rationale: Moving Beyond a “One-Size-Fits-All” Approach
Clear cell renal cell carcinoma (ccRCC) accounts for the majority of kidney cancer cases. Historically, robust biomarker data in RCC has been lacking; consequently, the medical community has generally adopted a “one-size-fits-all” approach to systemic therapy for metastatic patients.
However, for patients in the oligometastatic stage, this blanket approach may not be optimal. Accurate prognostic assessment is critical for determining local treatment strategies or the feasibility of delaying systemic therapy. KIM-1 is a transmembrane glycoprotein expressed in normal kidneys and ccRCC; its prognostic value has been previously demonstrated in pre-nephrectomy, post-nephrectomy, and metastatic settings. However, the application of ctDNA in ccRCC has faced challenges due to its “low shedding” phenotype, high genetic heterogeneity, and generally low mutation burden. This study sought to explore the synergistic prognostic potential of KIM-1 and ctDNA specifically in the oligometastatic ccRCC population to bridge this gap.
02 Methodology: Development and Validation of the K-COMPAsS Model
The research analyzed an investigator-initiated trial focused on oligometastatic ccRCC patients receiving local radiation therapy. Plasma KIM-1 protein levels were measured using an ELISA-based method. For ctDNA analysis, the Myriad assay was employed, utilizing up to 2,000 somatic variants derived from whole-genome sequencing for high-sensitivity detection.
The primary study endpoint was systemic therapy-free survival (STFS), with secondary endpoints including progression-free survival (PFS) and overall survival (OS). The team integrated baseline KIM-1, ctDNA, and key clinical prognostic factors to develop the K-COMPAsS model.
03 Dynamic Monitoring: Expression Characteristics of KIM-1 and ctDNA
Data revealed that the median baseline KIM-1 concentration was 126.9 pg/mL. Levels decreased modestly at the completion of radiation therapy and during the three-month follow-up.
Regarding ctDNA, it was detected in approximately 60% of patients at baseline. The median baseline ctDNA concentration was within the ultra-sensitive range at 18.1 ppm (parts per million), falling slightly to 15 ppm at the three-month follow-up. Statistical analysis confirmed a significant correlation between KIM-1 and ctDNA values.
04 Prognostic Association: Baseline Levels Correlate with Clinical Outcomes
The study confirmed that baseline KIM-1 is a robust prognostic indicator:
- Multiple Endpoint Correlation: KIM-1 levels at baseline and the 3-month follow-up were significantly associated with STFS, PFS, and OS.
- Independent Prognostic Factors: In multivariate analysis, both baseline KIM-1 and ctDNA were shown to be independently associated with STFS, whether measured at baseline or during follow-up.
05 Model Performance: K-COMPAsS Superiority Over Clinical Models
The final K-COMPAsS model integrated six variables, including KIM-1 and ctDNA.
- Discrimination Power: The K-COMPAsS model exhibited strong discrimination for STFS, achieving a C-index of 0.76.
- Comparative Advantage: This significantly outperformed the traditional clinical-only model (comprising four variables), which had a C-index of 0.66. These results demonstrate that incorporating biological markers (KIM-1 and ctDNA) markedly improves the accuracy of prognostic assessments in oligometastatic ccRCC.
06 Conclusion and Outlook: Paving the Way for De-escalation and Individualized Management
Professor Chad Tang concluded that this study represents the first analysis of KIM-1 within an oligometastatic ccRCC cohort and demonstrates the independent prognostic significance of combined ctDNA and KIM-1 monitoring for STFS.
Ultimately, these biomarkers and the K-COMPAsS model offer a way to hopefully thoughtfully and systematically de-escalate treatment in patients who will do well. By identifying patients who may benefit most from local therapies or who can safely delay systemic treatment, the model provides clinicians with a powerful tool to move away from generalist protocols toward precision medicine. The model is currently available for academic review and further validation at kcompass.org.
